To determine whether such a clinical trajectory could be translated to PCa, we then investigated the expression profiles of ERα in prostate tumors using the clinical pipeline for defining ERα expression status in patients with breast cancer at our local hospital, using a clinically validated antibody for this receptor (clone EP1, Dako). The gene discussed is ESR1; the disease is breast cancer.